Aspire Pharmaceuticals, Inc.

Warning LetterOpen

United StatesFEI 3003159106Issued Nov 22, 2022Division of Human and Animal Food Operations East II

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3003159106.

Violations0

Issue DateNov 22, 2022

Product TypeDietary Supplements

StatusOpen

Letter Details

Firm: Aspire Pharmaceuticals, Inc.
Location: United States
FEI Number: 3003159106
Country: United States
Issue Date: November 22, 2022
Issuing Office: Division of Human and Animal Food Operations East II
Product Type: Dietary Supplements
Status: Open

Summary

Based on limited metadata, the FDA issued a Warning Letter to Aspire Pharmaceuticals, Inc. on November 22, 2022, regarding dietary supplements. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The letter falls under FDA's dietary supplement regulatory authority, though the specific issuing office and violation details remain unknown. This summary should be supplemented with the complete Warning Letter for comprehensive compliance analysis.

Aspire Pharmaceuticals, Inc. FDA Warning Letter, November 22, 2022